+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07785180

Retrospective Observational Study of Adults With BPDCN Treated With Chemotherapy Agents

Led by Stemline Therapeutics, Inc. · Updated on 2026-09-15

140

Participants Needed

67

Research Sites

30 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of chemotherapy treatments in adults diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN. This observational study aims to provide comparative data to the ELZONRIS registry study by reviewing real-world outcomes of patients treated with various chemotherapy regimens as their first-line therapy since May 2016. Participants have received chemotherapy regimens similar to those used for acute myeloid leukemia, acute lymphocytic leukemia, or lymphoma, with choices made by their healthcare providers based on institutional practices. No study medication is provided by the sponsor. The study collects data retrospectively without administering new treatments. During the study, researchers collect information on response rates, duration of response, progression-free and overall survival, adverse events, transfusion needs, treatment durations, hospitalization details, and transitions to stem cell transplant. Data is gathered from the start of treatment through up to 26 months, offering insights into treatment patterns and outcomes. Participants privacy and consent are managed following local regulations.

CONDITIONS

Brief Title

A Non-interventional Study of Participants With BPDCN Treated With Chemotherapy

Research Team

S

Stemline Trials

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here